The Latest Breaking News from Pfizer Inc

May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month, bringing the total for the year to 15. This compares to the 24 NMEs the Food and…

Use of Pfizer Inc's COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time.

Pfizer Inc (NYSE:PFE) will sell over 20 patent-protected drugs and vaccines at not-for-profit prices to 45 of the world's poorest countries. Under the program, Pfizer will begin shipping the medicines first to Ghana, Malawi, Rwanda, Senegal, and Uganda before the end of this year, Chief Executive Albert Bourla said in an interview. This will…

Pfizer Inc plans to sell its entire portfolio of brand-name drugs at cost in as many as 45 lower-income countries, including Cambodia and Laos, one of the most comprehensive and ambitious drug-access programmes ever announced by a large pharmaceutical manufacturer.

Pfizer Inc will make all of its patented medicines including COVID-19 treatment Paxlovid and big-selling breast cancer drug Ibrance available at a not-for-profit price to 45 of the world's poorest countries, the drugmaker said on Wednesday.

Pfizer Inc (NYSE:PFE) has announced detailed results from two pivotal studies from ELEVATE UC Phase 3 program evaluating etrasimod for active ulcerative colitis (UC).  The drug, etrasimod, was Pfizer's key asset in its $6.7 billion deal for Arena Pharmaceuticals last year.  UC is an inflammatory bowel disease that affects around 3.8 million people in North…

Concert Pharmaceuticals Inc (NASDAQ:CNCE) has released highly positive Phase 3 data for their alopecia areata drug CTP-543 from the THRIVE-AA1 trial.  Mizuho says that the efficacy supports its view that CTP-543 potentially has best-in-class efficacy amongst the three main oral JAK inhibitors in late-stage development for alopecia areata (CTP-543, Eli Lilly And Co's (NYSE: LLY)…

Pfizer Inc. and BioNTech SE said their COVID-19 vaccine was highly effective and prompted a strong immune response in children under age 5, based on early results from a trial that is likely to pave the way for infants and toddlers to finally get immunized.

Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.

The Centers for Disease Control and Prevention recommended that children ages 5 to 11 receive the newly authorized COVID-19 booster shot from Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX). Following the recommendation, many of the nation's doctors, pharmacies, and other vaccination sites are expected to begin offering the extra doses to the 28 million U.S. children…

The U.S. National Institutes of Health and Pfizer Inc (NYSE:PFE) are discussing testing a longer course of COVID-19 antiviral treatment Paxlovid, required to prevent reinfections, White House Chief Medical Officer Anthony Fauci said. "We're going to be planning what studies we're going to be doing relatively soon, within the next few days," to…